LRRN3 and ovarian cancer: Our method is able to identify the known cancer drivers and further nominate candidates that exhibit higher breakpoint proximity than expected by random chance, such as DMD and LRRN3 in esophageal cancer, NF1 in ovarian cancer, CDK12 in uterine cancer, and WWOX in colorectal cancer.